Welcome to our dedicated page for CERUS SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cerus Corporation filings document financial and governance disclosures for a biomedical products company focused on transfusion safety. Recent 8-K reports furnish operating results, preliminary product revenue, revenue guidance, and business updates tied to the INTERCEPT Blood System, INTERCEPT Fibrinogen Complex, government contract revenue, product margins, and related pipeline activity.
The company’s proxy and material-event filings also cover annual meeting matters, board composition, executive compensation, severance arrangements, compensatory plans, and officer or director changes. These filings provide formal records of Cerus’ public-company governance, Nasdaq-listed common stock reporting, capital-structure disclosures, and material events connected to its blood-safety product business.
CERUS CORP executive Chrystal Jensen, Chief Legal Officer, reported a sale of 30,000 shares of common stock on 2026-08-17. The transaction was a planned trade pursuant to a Rule 10b5-1 plan and executed at a weighted average price of $2.9843 per share, with individual sale prices ranging from $2.92 to $3.04. After this sale, Jensen directly holds 936,657 shares of Cerus common stock.
CERS – Chrystal Nikole Jensen has filed a Form 144 notice to sell common stock. The filing lists a proposed sale of up to 30,000 shares of Cerus Corporation common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with a proposed transaction date of 08/17/2026. It also notes prior restricted stock awards of 14,781 shares on 03/12/2021 and 15,219 shares on 03/12/2022 from the issuer, and reports that 24,329 common shares were sold on 07/01/2026 within the past three months.
Baker Bros. Advisors LP and related reporting persons filed Amendment No. 13 reporting their beneficial ownership in Cerus Corporation common stock. They beneficially own 6,395,431 shares of common stock held by Baker Brothers Life Sciences, L.P. and 667, L.P., over which the Adviser has complete investment and voting discretion. This represents 3.2% of the 201,457,000 shares outstanding as of June 30, 2026. Julian C. Baker and Felix J. Baker each also beneficially own 19,864 shares individually, so each is reported as beneficially owning 6,415,295 shares, or 3.2% of the class. The filing states ownership of 5 percent or less of the class.
ARK Investment Management LLC and its CEO/CIO Catherine D. Wood report beneficial ownership of Cerus Corp common stock on an amended Schedule 13G/A. As of 06/30/2026, they collectively report beneficial ownership of 17,932,099 shares of Cerus common stock, representing 8.95% of the outstanding class.
ARK reports sole voting power over 16,642,316 shares and shared voting power over 226,246 shares. ARK also has sole dispositive power over all 17,932,099 shares and no shared dispositive power. Catherine Wood reports no sole voting or dispositive power, but shared voting power over 16,868,562 shares and shared dispositive power over 17,932,099 shares, reflecting her control of ARK. Both ARK and Wood list the same 17,932,099 shares as beneficially owned.
Cerus Corporation is the subject of an amended Schedule 13G filing by Soleus Capital Master Fund, L.P. and related entities, including Guy Levy. The group reports beneficial ownership of 2,500,000 shares of Cerus common stock, representing 1.2% of the outstanding shares, based on 201,524,898 shares outstanding as of July 16, 2026. All 2,500,000 shares are reported with shared voting and shared dispositive power and no sole voting or dispositive power. The reporting persons state that the shares are held directly by Soleus Capital Master Fund, L.P. and that the affiliated entities and Mr. Levy disclaim beneficial ownership except for purposes of Section 13(d). The filing also confirms that the group now holds 5% or less of the Cerus common stock class.
Cerus Corporation, developer of the INTERCEPT Blood System, reported higher product revenue while remaining loss-making for the quarter ended June 30, 2026. Product revenue was $57,441 (in thousands), up from $52,445 (in thousands) a year earlier, with additional government contract revenue of $5,862 (in thousands).
Loss from operations narrowed to $1,858 (in thousands), and net loss attributable to Cerus was $2,940 (in thousands), or $0.01 per basic and diluted share, compared with $0.03 a year earlier. Cash and cash equivalents were $17,980 (in thousands) and short-term investments $38,284 (in thousands). Total debt principal was $65,088 (in thousands), comprising a $35,000 (in thousands) term loan at an interest rate of approximately 9.4% and $30,088 (in thousands) outstanding under a revolving credit facility. Cerus also highlighted substantial non-dilutive funding capacity through BARDA and DoD contracts supporting red blood cell and cryoprecipitate programs.
Cerus Corporation reported Q2 2026 total revenue of $63.3 million, up 5% year over year, with product revenue of $57.4 million growing 10% and broad-based strength across product categories. INTERCEPT Fibrinogen Complex demand rose about 20%, and U.S. IFC sales reached $6.7 million versus $5.6 million.
Product gross profit was $29.5 million, though product gross margin declined to 51.4% from 55.2% due to currency and higher costs. Operating expenses fell 7% to $37.3 million, helping narrow net loss attributable to Cerus to $2.9 million, or $0.01 per share, while non-GAAP adjusted EBITDA improved to a positive $3.0 million.
Cash, cash equivalents and short-term investments totaled $56.3 million, with $35.0 million outstanding on the term loan and $30.1 million drawn on the revolver after a refinancing that reduced the term loan by $30 million. A BARDA contract expansion added $21.9 million of potential value to support INTERCEPT Red Blood Cell development. Management raised 2026 product revenue guidance to $229–$231 million, including higher IFC guidance of $23–$25 million, implying 11–12% and roughly 40–50% growth from 2025.
Cerus Corp reported that Chief Executive Officer Vivek K. Jayaraman completed a sale of 16666 shares of Common Stock on July 16, 2026 at $3.16 per share. The sale was executed pursuant to a 10b5-1 trading plan, and he now directly holds 2232211 shares.
Vivek K. Jayaraman has given notice of intention to sell up to 16,666 shares of CERS common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an aggregate market value of $52,664.56, on 07/16/2026.
The shares relate to restricted stock acquired from the issuer on 03/12/2021. During the past three months, Jayaraman sold 42,359 shares for $124,658.30 on 07/01/2026 and two blocks of 16,667 shares for $50,001.00 each on 05/29/2026 and 05/01/2026.
Cerus Corporation updated the employment terms for William “Obi” Greenman following his transition from President, Chief Executive Officer and Chairman to Executive Chairman effective July 1, 2026. Under an amendment to his employment letter, he will serve as Executive Chairman through May 31, 2027, with an anticipated time commitment averaging about 60% of a full-time schedule, unless earlier terminated or extended by written agreement. For this role, he will receive an annual base salary of $500,000 and, for 2026, will be eligible for an annual cash bonus with a target opportunity equal to 80% of his total 2026 base salary. He will not be entitled to earn an annual cash bonus for any portion of 2027. If his change in role triggers a qualifying event under the Consolidated Omnibus Reconciliation Act, Cerus will pay or reimburse his COBRA health insurance premiums, subject to his continued compliance with the amended letter agreement and his timely COBRA election. All other terms of the original letter agreement remain unchanged.